QUOTE AND NEWS
Motley Fool  Aug 31  Comment 
A positive clinical update for an experimental cholesterol treatment sent shares of The Medicines Co. higher today.
TheStreet.com  Aug 31  Comment 
NEW YORK (TheStreet) -- Medicines   stock is soaring by 16.14% to $39.08 on heavy trading volume on Monday morning, after the drug maker along with Alnylam Pharmaceuticals on Sunday announced positive initial results of ALN-PCSsc, a new...
Benzinga  Aug 31  Comment 
The Medicines Company (NASDAQ: MDCO) shares climbed 14.98 percent to $38.68. The volume of Medicines Company shares traded was 1555 percent higher than normal. Medicines Company announced positive ALN-PCSsc study results. Energy Focus Inc ...
Benzinga  Aug 31  Comment 
The Medicines Company (NASDAQ: MDCO) shares touched a new 52-week high of $38.964 following the announcement of positive ALN-PCSsc study results. Smith & Wesson Holding Corp (NASDAQ: SWHC) shares reached a new 52-week high of $18.22. Smith &...
Benzinga  Aug 31  Comment 
BioLife Solutions Inc (NASDAQ: BLFS) gained 65.66 percent to $3.28 in pre-market trading as the company reported that its customer's TiGenix Phase 3 clinical trial has met primary endpoint. Vital Therapies Inc (NASDAQ: VTL) shares jumped 22.58...
Benzinga  Aug 24  Comment 
The Medicines Company today announced it will present results of recent clinical studies from its cardiovascular product portfolio at the 2015 European Society of Cardiology (ESC) Congress in London, August 29 to September 2. The presentations...
TheStreet.com  Aug 19  Comment 
NEW YORK (TheStreet) -- The Medicines Co. price target was increased to $40 from $35 at Leerink, which reiterated its "outperform" rating. The company might unlock meaningful shareholder value as it is establishing proof of principle from its...
Market Intelligence Center  Aug 13  Comment 
After Wednesday’s trading in Medicines Company (MDCO) the algorithms behind MarketIntelligenceCenter.com's Artifical Intelligence Center picked out a trade that offers a 12.74% or 30% (for comparison purposes only), while providing 13.07%...
Benzinga  Jul 29  Comment 
Shares of The Medicines Company (NASDAQ: MDCO) tumbled more than 5 percent Wednesday after the company reported its second-quarter results before the market opened. Shares opened the day for trading at $32.77 and quickly moved lower to $31.08...




RELATED WIKI ARTICLES
 

Based in Parsippany, NJ, The Medicines Company (MDCO) is engaged in acquiring, developing, and marketing specialty pharmaceutical primarily for cardiovascular indications. Its leading product, Angiomax (bivalirudin), which was acquired from Biogen Idec, Inc. in 1996, is used as an anticoagulant in patients undergoing coronary angioplasty. The company's other late-stage products include Clevidipine and Cangrelor, both acquired from AstraZeneca several years ago. Clevidipine is an intravenous drug (calcium channel blocker) intended for the short-term control of blood pressure in patients undergoing cardiac surgery. Cangrelor is an intravenous anticoagulant, having potential uses in coronary angioplasty and cardiac surgery. The company sells its products through its own sales force and distributors. In 2006, sales of Angiomax helped generate $214.0 million revenue.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki